CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

50-722/S-005

50-723/S-005

50-758/S-004

50-759/S-006

APPROVAL LETTER

NDA 50-722/S-005
NDA 50-723/S-005
NDA 50-758/S-004
NDA 50-759/S-006

Syntex (U.S.A.) LLC
Attention: Carmen Rodriguez, M.Sc.
Regulatory Program Director
3401 Hillview Avenue
Palo Alto, California 94304

JUL 2 8 2000

Dear Ms. Rodriguez:

Please refer to your supplemental new drug application dated October 1, 1999, which was received on October 4, 1999 for CellCept® (mycophenolate mofetil) Capsules, 250 mg (NDA 50-722/S-005). Refer also to your supplemental new drug application dated May 19, 2000, which was received on May 24, 2000, for CellCept® (mycophenolate mofetil) Intravenous (NDA 50-758/S-004). Additionally, refer to your supplemental new drug applications dated June 22, 2000, which were received on June 23, 2000, for CellCept® (mycophenolate mofetil) Tablets, 500 mg, and CellCept® (mycophenolate mofetil) Oral Solution, 200 mg/mL (NDAs 50-723/S-005 and 50-759/S-006). These supplements were submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act. We note that these applications are subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

We acknowledge receipt of your submissions dated as follows.

December 7, 1999	March 1, 2000	April 26, 2000	July 7, 2000 (2)
January 31, 2000	March 20, 2000	May 19, 2000	July 19, 2000
February 4, 2000	April 17, 2000	June 29, 2000	July 28, 2000

These supplemental new drug applications provide for the use of CellCept® (mycophenolate mofetil) Capsules, Intravenous, Tablets, and Oral Solution for prophylaxis of organ rejection in patients receiving allogeneic hepatic transplants.

We have completed the review of these applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these applications are approved effective on the date of this letter. The final printed labeling (FPL) must be identical to the text of the package insert submitted July 28, 2000.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Individually mount ten of the copies on heavyweight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplemental NDAs 50-722/S-005; 50-723/S-005; 50-758/S-004; 50-759/S-006." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitments specified in your submission dated July 28, 2000. These commitments are listed below.

1. You will collect and report 3-year follow-up safety and efficacy data from the ongoing Phase 3 Study MYCS2646, whether or not patients remain on study drug.

2. You will conduct an appropriate study or studies on the pharmacokinetics and safety of CellCept® in African American liver transplant recipients.

3. You will conduct an appropriate study or studies on the pharmacokinetics and safety of CellCept® in pediatric liver transplant recipients less than 12 years old, especially pediatric patients less than 3 years old with biliary atresia.

Protocols, data, and final reports should be submitted to your IND for this product and a copy of the cover letter sent to this NDA. If an IND is not required to meet your Phase 4 commitments, please submit protocols, data and final reports to this NDA as correspondence. In addition, under 21 CFR 314.81(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include the number of patients entered in each study, expected completion and submission dates, and any changes in plans since the last annual report. For administrative purposes, all submissions, including labeling supplements, relating to these Phase 4 commitments must be clearly designated "Phase 4 Commitments."

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens must contain an assessment of the safety and effectiveness of the product in pediatric patients unless FDA waives or defers the requirement (63 FR 66632) [21 CFR 314.55]. We are waiving the pediatric study requirement for this action on these applications for neonates 0 to 1 month of age. In addition, we are deferring submission of your pediatric studies until May 31, 2003, for children between the ages of 1 month and 16 years.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, please contact Matthew A. Bacho, Regulatory Project Manager, at (301) 827-2127.

Sincerely,

/S/ 7/28/00

Renata Albrecht, M.D.
Acting Director
Division of Special Pathogen and
Immunologic Drug Products
Office of Evaluation IV
Center for Drug Evaluation and Research